Results 151 to 160 of about 194,414 (305)

Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Summary Background: Pulmonary arterial hypertension (PAH) is a vascular disease characterised by restricted flow and high pressure through the pulmonary arteries, leading to progressive right heart failure and death. This study reports the global burden
GBD 2021 Pulmonary Arterial Hypertension Collaborators
core   +1 more source

Low-grade albuminuria in pulmonary arterial hypertension

, 2019
Low-grade albuminuria, determined by the urinary albumin to creatinine ratio, has been linked to systemic vascular dysfunction and is associated with cardiovascular mortality.
Fessel, Joshua P., Cogan, Joy D., Nickel, Nils P., de Caestecker, Mark P., Austin, Eric D., West, James D., Hamid, Rizwam   +6 more
core   +1 more source

Right ventricle in pulmonary hypertension

, 2011
During heart development chamber specification is controlled and directed by a number of genes and a fetal heart gene expression pattern is revisited during heart failure.
Drake, Jennifer I, Norbert F. Voelkel, Herman J. Bogaard, Voelkel, Norbert F, Natarajan, Ramesh, Ramesh Natarajan, Jennifer I. Drake, Bogaard, Herman J   +7 more
core   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Non-invasive stroke volume assessment in patients with pulmonary arterial hypertension: left-sided data mandatory

, 2008
Background Cardiovascular Magnetic Resonance (CMR) is an emerging modality in the diagnosis and follow-up of patients with Pulmonary Arterial Hypertension (PAH).
Mauritz, G.J., Mauritz Gert-Jan, Gert-Jan Mauritz, Anco Boonstra, Boonstra Anco, Vonk Noordegraaf, A., Marcus, J.T., Anton Vonk-Noordegraaf, Postmus Pieter E, Pieter E Postmus, Vonk-Noordegraaf Anton, Marcus J Tim, Westerhof Nico, J Tim Marcus, Postmus, P.E., Westerhof, N., Nico Westerhof, Boonstra, A.   +17 more
core   +1 more source

The striated muscles in pulmonary arterial hypertension: adaptations beyond the right ventricle

, 2015
Pulmonary arterial hypertension (PAH) is a fatal lung disease characterised by progressive remodelling of the small pulmonary vessels. The daily-life activities of patients with PAH are severely limited by exertional fatigue and dyspnoea.
Vonk Noordegraaf, A., Harm-Jan Bogaard, Anton Vonk-Noordegraaf, Bogaard, H.J., de Man, F.S., Handoko, M.L., Frances S. de Man, Rain, S., Stienen, G.J.M., Silvia Rain, Coen A.C. Ottenheijm, Emmy Manders, Manders, E., Ger J.M. Stienen, Ottenheijm, C.A.C., M. Louis Handoko   +15 more
core   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source